Last reviewed · How we verify
Cyanokit (HYDROXOCOBALAMIN)
Cyanokit (HYDROXOCOBALAMIN) is an antidote medication originally developed by WATSON LABS and currently owned by Btg Intl. It is a small molecule drug classified as an antidote, approved by the FDA in 1978 for indications including cobalamin deficiency, pernicious anemia, prevention of vitamin B12 deficiency, and toxic effects of cyanide. The medication is off-patent, with multiple generic manufacturers available. Key safety considerations include the potential for allergic reactions and interactions with other medications. Cyanokit is used to treat cyanide poisoning by binding to the cyanide ion and forming a stable complex.
At a glance
| Generic name | HYDROXOCOBALAMIN |
|---|---|
| Sponsor | Btg Intl |
| Drug class | Antidote |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1978 |
Approved indications
- Cobalamin deficiency
- Pernicious anemia
- Prevention of Vitamin B12 Deficiency
- Toxic effect of cyanide
Common side effects
- Chromaturia (red colored urine)
- Erythema
- Oxalate crystals in urine
- Rash
- Blood pressure increased
- Nausea
- Headache
- Infusion site reaction
- Lymphocyte percent decreased
- Ventricular extrasystoles
- Electrocardiogram repolarization abnormality
- Heart rate increased
Key clinical trials
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Clinical and Laboratory Study of Methylmalonic Acidemia
- Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older
- Effect of Vitamin D and Folic Acid on Mild Cognitive Impairment (NA)
- Frequency of Fibromyalgia Syndrome in Elderly Patients Aged 80 and Above and Its Relationship With Geriatric Parameters
- Vegan Diet and Immune-Inflammatory Outcomes in Asthma and Healthy Adults (NA)
- Microbiome and Health Indicators in People With Obesity, Prediabetes and Type 2 Diabetes Undergoing a Lifestyle Intervention (NA)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyanokit CI brief — competitive landscape report
- Cyanokit updates RSS · CI watch RSS
- Btg Intl portfolio CI